The Board of Directors of PI Industries Ltd. convened on February 12, 2026, to approve the Unaudited Financial Results for the quarter and nine months ended December 31, 2025. A key highlight was the declaration of an interim dividend of ₹5.00 per equity share (500% on face value of ₹1.00), payable by March 13, 2026. The record date for this dividend entitlement has been set as Monday, February 23, 2026. The standalone PAT for the quarter stood at ₹2,816 Million.
Board Meeting Outcome and Dividend Declaration
The Board of Directors of PI Industries Limited met today, February 12, 2026, concluding the meeting at 6:30 P.M. (IST). The Board primarily focused on the financial outcomes for the third quarter (Q3) of the financial year 2025-26.
The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Crucially, the Board declared an interim dividend at the rate of ₹5.00 (Rupees five only) per share, representing 500% of the face value of Re. 1/- per share. This dividend is scheduled to be paid to eligible members on or before Friday, March 13, 2026. The record date for determining eligibility for this dividend is fixed as Monday, February 23, 2026.
Standalone Financial Highlights (In Million)
The standalone performance shows significant figures for the quarter ended December 31, 2025, compared to the same period last year:
- Total Income stood at ₹13,459 Million (compared to ₹18,526 Million in Q3 FY2025).
- Profit Before Exceptional Item and Tax (PBT) was ₹3,655 Million (compared to ₹5,483 Million in Q3 FY2024).
- The Profit for the period/year (PAT) for the quarter was ₹2,816 Million (compared to ₹4,238 Million in Q3 FY2024).
- Earnings Per Share (Basic and Diluted) for the quarter stood at ₹18.56.
For the nine months ended December 31, 2025, the standalone PAT reached ₹12,370 Million.
Consolidated Financial Highlights (In Million)
The consolidated results reflect the overall group performance:
- Total Income for the quarter ended December 31, 2025, was ₹14,424 Million.
- Consolidated Profit Before Exceptional Items and Tax for the quarter was ₹2,578 Million.
- A significant Exceptional Item Gain of ₹1,051 Million was recorded, primarily driven by a write-back of contingent consideration related to the acquisition of Solis Pharmachem and the recognition of incremental liability due to new Labour Codes.
- Consolidated Profit After Exceptional Items Before Tax (PBT) for the quarter reached ₹3,629 Million.
- The Profit for the period/year (PAT) for the quarter was ₹3,113 Million.
- Consolidated Earnings Per Share (Basic and Diluted) for the quarter was ₹20.52.
Over the nine months ended December 31, 2025, the consolidated PAT reached ₹11,206 Million.
Business Segment Performance (Consolidated)
The results detail performance across the two operating segments:
- Agro Chemicals: This segment contributed the majority of revenue and profit. For the quarter, Profit Before Tax (after inter-segment adjustments) was ₹3,629 Million, with Segment Assets valued at ₹1,19,068 Million.
- Pharma: The Pharma segment reported a segment loss before tax of (₹819 Million) for the quarter, despite an increase in Segment Assets to ₹14,012 Million.
Exceptional Items Explained
The standalone results included an Exceptional Item Loss of ₹206 Million, related to the reassessment of employee benefit obligations due to the notification of the New Labour Codes, effective November 21, 2025. In the consolidated results, an Exceptional Item Gain of ₹1,051 Million was recognized, which includes the write-back of contingent consideration related to the Pl Health Sciences Limited (PIHS) acquisition and the incremental liability adjustment.
Source: BSE
